Some slighting asides were made during one session at BIO, on biopharma capacity...they weren't part of the official powerpoint presentations, but came unofficially during the Q&A, and they showed that some people in the industry may continue to see Ireland as an expensive place to do business.
Publicist and NYU business school adjunct professor Paul Osterreicher had a very interesting analysis of FDA's communications and public relations crisis in PR Week. So why should I care about FDA's problems, you ask? Because some of them are pharma's problems too...
Did anyone miss President Obama's recent announcement that he plans to put an end to corporate tax loopholes (a mainstay for every major pharma and biotech company in the world....)More from Bloomberg and the President himself.
How did we ever live without DVD's and the "movie behind the movie" clips? Pfizer recently publicized a behind-the-scenes look at how it filmed its recent controversial public service ad, aimed at stopping online counterfeit drug sales. Now Click here to watch the film behind the film.
Am looking forward to BIO, and to hearing from the brilliant, quirky, altruistic and non-altruistic people who are driving that industry forward. But while developing an article on compliance trends, found a gem of an article in The Scientist that looks at the "flip side" of the industry: criminals...
Some of those in favor of relaxed reimportation often argue that the drug industry is fear mongering when it points to potential safety problems with drugs or ingredients sourced from abroad. "Be afraid, be very afraid.
More evidence that the drug industry and EPA need to redefine acceptable emissions limits for APIs, collaborate on intelligent and cost effective detection and analytical methods and proactively address a controversial subject that will not go away.
It was sad to read (a few days late) of the world's latest pharma quality disaster: the discovery that talc used in over a thousand pharmaceutical and personal care products sold in South Korea contained asbestos. Click here for local coverage.
From Chemical Engineering Progress, Girish Malhotra presents his prescription for the pharmaceutical industry----QbD, PAT and control all play a key role, and chemical engineers will make it happen. The ultimate goal will be entirely new business models for pharma.